tetano
Editor, Senior Moderator
Int J Infect Dis
. 2024 Jul 3:107160.
doi: 10.1016/j.ijid.2024.107160. Online ahead of print. Relative vaccine effectiveness of MF59®-adjuvanted vs high-dose trivalent inactivated influenza vaccines for prevention of test-confirmed influenza hospitalizations during the 2017-2020 influenza seasons
Ian McGovern[SUP] 1 [/SUP], Benjamin Chastek[SUP] 2 [/SUP], Tim Bancroft[SUP] 2 [/SUP], Noah Webb[SUP] 2 [/SUP], Mahrukh Imran[SUP] 3 [/SUP], Stephen I Pelton[SUP] 4 [/SUP], Mendel D M Haag[SUP] 5 [/SUP]
Affiliations
Objectives: This study evaluated relative vaccine effectiveness (rVE) of MF59-adjuvanted trivalent inactivated influenza vaccine (aTIV) vs high-dose trivalent inactivated influenza vaccine (HD-TIV) for prevention of test-confirmed influenza emergency department visits and/or inpatient admissions ("ED/IP") and for IP admissions alone pooled across the 2017-2020 influenza seasons. Exploratory individual season analyses were also performed.
Methods: This retrospective test-negative design study included US adults age ≥65 years vaccinated with aTIV or HD-TIV who presented to an ED or IP setting with acute respiratory or febrile illness during the 2017-2020 influenza seasons. Test-positive cases and test-negative controls were grouped by vaccine received. The rVE of aTIV vs HD-TIV was evaluated using a combination of inverse probability of treatment weighting and logistic regression to adjust for potential confounders.
Results: Pooled analyses over the 3 seasons found no significant differences in the rVE of aTIV vs HD-TIV for prevention of test-confirmed influenza ED/IP (-2.5% [-19.6, 12.2]) visits and admissions or IP admissions alone (-1.6% [-22.5, 15.7]). The exploratory individual season analyses also showed no significant differences.
Conclusions: Evidence from the 2017-2020 influenza seasons indicates aTIV and HD-TIV are comparable for prevention of test-confirmed influenza ED/IP visits in US adults age ≥65 years.
Keywords: adjuvanted influenza vaccine, influenza, hospitalizations; high-dose influenza vaccine, older adults; relative vaccine effectiveness.
. 2024 Jul 3:107160.
doi: 10.1016/j.ijid.2024.107160. Online ahead of print. Relative vaccine effectiveness of MF59®-adjuvanted vs high-dose trivalent inactivated influenza vaccines for prevention of test-confirmed influenza hospitalizations during the 2017-2020 influenza seasons
Ian McGovern[SUP] 1 [/SUP], Benjamin Chastek[SUP] 2 [/SUP], Tim Bancroft[SUP] 2 [/SUP], Noah Webb[SUP] 2 [/SUP], Mahrukh Imran[SUP] 3 [/SUP], Stephen I Pelton[SUP] 4 [/SUP], Mendel D M Haag[SUP] 5 [/SUP]
Affiliations
- PMID: 38969330
- DOI: 10.1016/j.ijid.2024.107160
Objectives: This study evaluated relative vaccine effectiveness (rVE) of MF59-adjuvanted trivalent inactivated influenza vaccine (aTIV) vs high-dose trivalent inactivated influenza vaccine (HD-TIV) for prevention of test-confirmed influenza emergency department visits and/or inpatient admissions ("ED/IP") and for IP admissions alone pooled across the 2017-2020 influenza seasons. Exploratory individual season analyses were also performed.
Methods: This retrospective test-negative design study included US adults age ≥65 years vaccinated with aTIV or HD-TIV who presented to an ED or IP setting with acute respiratory or febrile illness during the 2017-2020 influenza seasons. Test-positive cases and test-negative controls were grouped by vaccine received. The rVE of aTIV vs HD-TIV was evaluated using a combination of inverse probability of treatment weighting and logistic regression to adjust for potential confounders.
Results: Pooled analyses over the 3 seasons found no significant differences in the rVE of aTIV vs HD-TIV for prevention of test-confirmed influenza ED/IP (-2.5% [-19.6, 12.2]) visits and admissions or IP admissions alone (-1.6% [-22.5, 15.7]). The exploratory individual season analyses also showed no significant differences.
Conclusions: Evidence from the 2017-2020 influenza seasons indicates aTIV and HD-TIV are comparable for prevention of test-confirmed influenza ED/IP visits in US adults age ≥65 years.
Keywords: adjuvanted influenza vaccine, influenza, hospitalizations; high-dose influenza vaccine, older adults; relative vaccine effectiveness.